Description
Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.
Cyan = gene · Slate = variant · Green = drug · Click variant to filter table
Variants (3)
| CIViC ID | Name | HGVS | Type(s) |
|---|---|---|---|
| 2746 | Amplification | ||
| 21 | OVEREXPRESSION | ||
| 22 | PROMOTER DEMETHYLATION |